{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:30:33Z","timestamp":1787704233567,"version":"build-2784847793"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00535-017-1427-x","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T10:43:33Z","timestamp":1514976213000},"page":"591-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Treatment of hepatitis C in special populations"],"prefix":"10.1007","volume":"53","author":[{"given":"Goki","family":"Suda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"issue":"1 Suppl","key":"1427_CR1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45\u201357.","journal-title":"J Hepatol"},{"issue":"4","key":"1427_CR2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333\u201342.","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"1427_CR3","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","volume":"36","author":"LB Seeff","year":"2002","unstructured":"Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35\u201346.","journal-title":"Hepatology"},{"key":"1427_CR4","doi-asserted-by":"crossref","unstructured":"Kim WR, Stock PG, Smith JM, et al. OPTN\/SRTR 2011 annual data report: liver. Am J Transpl. 2013;13(Suppl 1):73\u2013102 Epub 2013\/01\/31.","DOI":"10.1111\/ajt.12021"},{"issue":"3","key":"1427_CR5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12072-015-9684-3","volume":"10","author":"K Gill","year":"2016","unstructured":"Gill K, Ghazinian H, Manch R, et al. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10(3):415\u201323.","journal-title":"Hepatol Int"},{"key":"1427_CR6","unstructured":"Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008(109):S1\u2013S99"},{"issue":"1","key":"1427_CR7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10157-007-0005-6","volume":"12","author":"Y Iwasa","year":"2008","unstructured":"Iwasa Y, Otsubo S, Sugi O, et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol. 2008;12(1):53\u20137.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"1427_CR8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.ajkd.2006.07.004","volume":"48","author":"A Napoli Di","year":"2006","unstructured":"Di Napoli A, Pezzotti P, Di Lallo D, et al. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis. 2006;48(4):629\u201337.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1427_CR9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","volume":"65","author":"RB Fissell","year":"2004","unstructured":"Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335\u201342.","journal-title":"Kidney Int"},{"key":"1427_CR10","doi-asserted-by":"crossref","unstructured":"Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831\u20137.","DOI":"10.1086\/339042"},{"key":"1427_CR11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev.med.59.081906.081110","volume":"59","author":"DL Thomas","year":"2008","unstructured":"Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med. 2008;59:473\u201385.","journal-title":"Annu Rev Med"},{"issue":"10","key":"1427_CR12","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1681\/ASN.V11101896","volume":"11","author":"E Nakayama","year":"2000","unstructured":"Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11(10):1896\u2013902.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1427_CR13","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1097\/01.ASN.0000100127.54107.57","volume":"14","author":"DA Goodkin","year":"2003","unstructured":"Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14(12):3270\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1427_CR14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","volume":"29","author":"P Mathurin","year":"1999","unstructured":"Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29(1):257\u201363.","journal-title":"Hepatology"},{"issue":"3","key":"1427_CR15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","volume":"35","author":"M Garcia-Retortillo","year":"2002","unstructured":"Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35(3):680\u20137.","journal-title":"Hepatology"},{"issue":"4 Pt 1","key":"1427_CR16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1053\/jhep.2000.17924","volume":"32","author":"M Berenguer","year":"2000","unstructured":"Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32(4 Pt 1):852\u20138.","journal-title":"Hepatology"},{"issue":"5","key":"1427_CR17","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jhep.2012.12.014","volume":"58","author":"M Berenguer","year":"2013","unstructured":"Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013;58(5):1028\u201341.","journal-title":"J Hepatol"},{"issue":"4","key":"1427_CR18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","volume":"30","author":"Y Benhamou","year":"1999","unstructured":"Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054\u20138.","journal-title":"Hepatology"},{"issue":"4","key":"1427_CR19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","volume":"33","author":"CS Graham","year":"2001","unstructured":"Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562\u20139.","journal-title":"Clin Infect Dis"},{"issue":"9939","key":"1427_CR20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","volume":"384","author":"CJ Smith","year":"2014","unstructured":"Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241\u20138.","journal-title":"Lancet"},{"issue":"2","key":"1427_CR21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2007.11.003","volume":"51","author":"CE Gordon","year":"2008","unstructured":"Gordon CE, Uhlig K, Lau J, et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008;51(2):263\u201377.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1427_CR22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3748\/wjg.14.255","volume":"14","author":"C Ayaz","year":"2008","unstructured":"Ayaz C, Celen MK, Yuce UN, et al. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol. 2008;14(2):255\u20139.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1427_CR23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/hep.20107","volume":"39","author":"N Brau","year":"2004","unstructured":"Brau N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV\/HCV-coinfection with interferon alpha-2b\u00a0+\u00a0full-course vs. 16-week delayed ribavirin. Hepatology. 2004;39(4):989\u201398.","journal-title":"Hepatology"},{"issue":"11","key":"1427_CR24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jvh.12312","volume":"21","author":"M Omata","year":"2014","unstructured":"Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762\u20138.","journal-title":"J Viral Hepat"},{"issue":"17","key":"1427_CR25","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594\u2013603.","journal-title":"N Engl J Med"},{"issue":"20","key":"1427_CR26","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879\u201388.","journal-title":"N Engl J Med"},{"issue":"6","key":"1427_CR27","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083\u201391.","journal-title":"Hepatology"},{"key":"1427_CR28","doi-asserted-by":"crossref","unstructured":"Kumada H, Chayama K, Rodrigues-Jr L, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for HCV genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62(4):1037\u201346.","DOI":"10.1002\/hep.27972"},{"issue":"6","key":"1427_CR29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645\u201353.","journal-title":"Lancet Infect Dis"},{"key":"1427_CR30","doi-asserted-by":"crossref","unstructured":"Suda G, Nagasaka A, Yamamoto Y, et al. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. Hepatol Res. 2017;47(11):1127\u201336.","DOI":"10.1111\/hepr.12851"},{"key":"1427_CR31","doi-asserted-by":"crossref","unstructured":"Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150(7):1590\u20138.","DOI":"10.1053\/j.gastro.2016.02.078"},{"key":"1427_CR32","doi-asserted-by":"crossref","unstructured":"Suda G, Furusyo N, Toyoda H, et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol. 2017;53(1):119\u201328.","DOI":"10.1007\/s00535-017-1353-y"},{"issue":"7","key":"1427_CR33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","volume":"51","author":"G Suda","year":"2016","unstructured":"Suda G, Kudo M, Nagasaka A, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016;51(7):733\u201340.","journal-title":"J Gastroenterol"},{"key":"1427_CR34","unstructured":"Suda G, Ogawa K, Kimura M, et al. Novel treatment of hepatitis C virus infection for patients with renal impairment. J Clin Transl Hepatol. 2016;4(4):320\u20137."},{"issue":"12","key":"1427_CR35","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jama.2015.1373","volume":"313","author":"A Osinusi","year":"2015","unstructured":"Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232\u20139.","journal-title":"JAMA"},{"issue":"8","key":"1427_CR36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","volume":"373","author":"S Naggie","year":"2015","unstructured":"Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705\u201313.","journal-title":"N Engl J Med"},{"key":"1427_CR37","doi-asserted-by":"crossref","unstructured":"Sogni P, Gilbert C, Lacombe K, et al. All-oral direct-acting antiviral regimens in HIV\/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH cohort. Clin Infect Dis. 2016;63(6):763\u201370.","DOI":"10.1093\/cid\/ciw379"},{"issue":"3","key":"1427_CR38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649\u201359.","journal-title":"Gastroenterology"},{"issue":"25","key":"1427_CR39","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","volume":"371","author":"PY Kwo","year":"2014","unstructured":"Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375\u201382.","journal-title":"N Engl J Med"},{"issue":"4","key":"1427_CR40","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2004.12.014","volume":"45","author":"S Bergman","year":"2005","unstructured":"Bergman S, Accortt N, Turner A, et al. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis. 2005;45(4):684\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1427_CR41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1542-4758.2010.00437.x","volume":"14","author":"SM Alavian","year":"2010","unstructured":"Alavian SM, Kabir A, Ahmadi AB, et al. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int. 2010;14(3):253\u201362.","journal-title":"Hemodial Int"},{"issue":"4","key":"1427_CR42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/j.ajkd.2012.08.040","volume":"61","author":"F Fabrizi","year":"2013","unstructured":"Fabrizi F, Plaisier E, Saadoun D, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61(4):623\u201337.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1427_CR43","doi-asserted-by":"crossref","first-page":"e100790","DOI":"10.1371\/journal.pone.0100790","volume":"9","author":"JJ Lee","year":"2014","unstructured":"Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9(6):e100790.","journal-title":"PLoS One"},{"issue":"5","key":"1427_CR44","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1681\/ASN.2006070736","volume":"18","author":"K Kalantar-Zadeh","year":"2007","unstructured":"Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007;18(5):1584\u201393.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1427_CR45","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","volume":"14","author":"F Fabrizi","year":"2007","unstructured":"Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14(10):697\u2013703.","journal-title":"J Viral Hepat"},{"issue":"4","key":"1427_CR46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1744-9987.2012.01078.x","volume":"16","author":"T Akiba","year":"2012","unstructured":"Akiba T, Hora K, Imawari M, et al. 2011 Japanese Society for Dialysis Therapy guidelines for the treatment of hepatitis C virus infection in dialysis patients. Ther Apher Dial. 2012;16(4):289\u2013310.","journal-title":"Ther Apher Dial"},{"issue":"10003","key":"1427_CR47","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537\u201345.","journal-title":"Lancet"},{"key":"1427_CR48","unstructured":"Merck & Co. Prescribing information for Rebetol\u00ae (ribavirin USP) capsules, for oral use. Kenilworth: Merck & Co.; 2016."},{"issue":"6","key":"1427_CR49","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/1744-9987.12318","volume":"19","author":"F Fabrizi","year":"2015","unstructured":"Fabrizi F, Dixit V, Messa P, et al. Pegylated interferon mono-therapy of chronic hepatitis C in the dialysis population: systematic review and meta-analysis. Ther Apher Dial. 2015;19(6):611\u201321.","journal-title":"Ther Apher Dial"},{"issue":"1","key":"1427_CR50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","volume":"56","author":"H Kumada","year":"2012","unstructured":"Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56(1):78\u201384.","journal-title":"J Hepatol"},{"issue":"13","key":"1427_CR51","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195\u2013206.","journal-title":"N Engl J Med"},{"issue":"13","key":"1427_CR52","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207\u201317.","journal-title":"N Engl J Med"},{"issue":"8","key":"1427_CR53","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/hepr.12421","volume":"45","author":"G Suda","year":"2015","unstructured":"Suda G, Yamamoto Y, Nagasaka A, et al. Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. Hepatol Res. 2015;45(8):837\u201345.","journal-title":"Hepatol Res"},{"issue":"2","key":"1427_CR54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcv.2012.10.009","volume":"56","author":"J Dumortier","year":"2013","unstructured":"Dumortier J, Guillaud O, Gagnieu MC, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol. 2013;56(2):146\u20139.","journal-title":"J Clin Virol"},{"key":"1427_CR55","doi-asserted-by":"crossref","unstructured":"Wiegand J, Maasoumy B, Buggisch P, et al. Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. Aliment Pharmacol Ther. 2014;39(11):1342\u20134.","DOI":"10.1111\/apt.12748"},{"issue":"1","key":"1427_CR56","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.dld.2013.08.133","volume":"46","author":"J Knapstein","year":"2014","unstructured":"Knapstein J, Galle PR, Zimmermann T. Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation. Dig Liver Dis. 2014;46(1):88\u20139.","journal-title":"Dig Liver Dis"},{"key":"1427_CR57","unstructured":"Merck & Co. US prescribing information for Zepatier\u2122 (elbasvir and grazoprevir) tablets, for oral use. Kenilworth: Merck & Co.; 2016."},{"issue":"8","key":"1427_CR58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2468-1253(17)30116-4","volume":"2","author":"A Bruchfeld","year":"2017","unstructured":"Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4\u20135 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2(8):585\u201394.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1427_CR59","unstructured":"AbbVie Inc. Prescribing information for VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use. North Chicago: AbbVie Inc.; 2016."},{"key":"1427_CR60","doi-asserted-by":"crossref","unstructured":"Atsukawa M, Tsubota A, Koushima Y, et al. Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res. 2017;47(13):1429\u201337.","DOI":"10.1111\/hepr.12910"},{"issue":"6","key":"1427_CR61","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jvh.12664","volume":"24","author":"R Munoz-Gomez","year":"2017","unstructured":"Munoz-Gomez R, Rincon D, Ahumada A, et al. Therapy with ombitasvir\/paritaprevir\/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: a multicentre experience. J Viral Hepat. 2017;24(6):464\u201371.","journal-title":"J Viral Hepat"},{"key":"1427_CR62","unstructured":"Bristol-Myers Squibb Co. Japanese prescribing information for Sunvepra capsules (asunaprevir). New Brunswick: Bristol-Myers Squibb Co.; 2014."},{"key":"1427_CR63","unstructured":"Bristol-Myers Squibb Co. Japanese prescribing information for Daklinza tablets (daclatasvir). New Brunswick: Bristol-Myers Squibb Co.; 2014."},{"issue":"9954","key":"1427_CR64","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384(9954):1597\u2013605.","journal-title":"Lancet"},{"key":"1427_CR65","doi-asserted-by":"crossref","unstructured":"Suda G, Nagasaka A, Yamamoto Y, et al. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus infected patients with renal impairment. Hepatol Res. 2017;47(11):1127\u201336.","DOI":"10.1111\/hepr.12851"},{"issue":"7","key":"1427_CR66","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00535-016-1174-4","volume":"51","author":"H Toyoda","year":"2016","unstructured":"Toyoda H, Kumada T, Tada T, et al. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol. 2016;51(7):741\u20137.","journal-title":"J Gastroenterol"},{"key":"1427_CR67","doi-asserted-by":"crossref","unstructured":"Kawakami Y, Imamura M, Ikeda H, et al. Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study. J Viral Hepat. 2016;23(11):850\u20136.","DOI":"10.1111\/jvh.12553"},{"key":"1427_CR68","doi-asserted-by":"crossref","unstructured":"Miyazaki R, Miyagi K. Effect and safety of daclatasvir-asunaprevir combination therapy for chronic hepatitis C virus genotype 1b-infected patients on hemodialysis. Ther Apher Dial. 2016;20(5):462\u20137.","DOI":"10.1111\/1744-9987.12407"},{"key":"1427_CR69","unstructured":"Gilead Sciences, Inc. Prescribing information for Harvoni combination tablets\u00ae (sofosbuvir\u00a0+\u00a0ledipasvir), for oral use. Foster City: Gilead Sciences, Inc.; 2015."},{"issue":"1","key":"1427_CR70","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","volume":"65","author":"A Desnoyer","year":"2016","unstructured":"Desnoyer A, Pospai D, Le MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65(1):40\u20137.","journal-title":"J Hepatol"},{"issue":"6","key":"1427_CR71","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","volume":"36","author":"V Saxena","year":"2016","unstructured":"Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36(6):807\u201316.","journal-title":"Liver Int"},{"issue":"6","key":"1427_CR72","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","volume":"36","author":"HE Nazario","year":"2016","unstructured":"Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR\u00a0<\u00a030\u00a0ml\/min. Liver Int. 2016;36(6):798\u2013801.","journal-title":"Liver Int"},{"issue":"6","key":"1427_CR73","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/liv.13078","volume":"36","author":"T Singh","year":"2016","unstructured":"Singh T, Guirguis J, Anthony S, et al. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver Int. 2016;36(6):802\u20136.","journal-title":"Liver Int"},{"key":"1427_CR74","doi-asserted-by":"crossref","unstructured":"Kosloski MDS, Zhao W. Pharmacokinetics, safety, and tolerability of next generation direct acting antivirals ABT-493 and ABT-530 in subjects with renal impairment. J Hepatol. 2016;64(2):S405\u20136.","DOI":"10.1016\/S0168-8278(16)00643-7"},{"key":"1427_CR75","unstructured":"Gane EJ, Lawitz E, Pugatch D, et al. EXPEDITION-IV: safety and efficacy of GLE\/PIB in adults with renal impairment and chronic hepatitis C virus genotype 1\u20136 infection. Hepatology 2016;64(6):1125A."},{"issue":"2","key":"1427_CR76","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.23020","volume":"50","author":"J Berenguer","year":"2009","unstructured":"Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407\u201313.","journal-title":"Hepatology"},{"issue":"4","key":"1427_CR77","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.2012.7844","volume":"308","author":"BN Limketkai","year":"2012","unstructured":"Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV\/HCV. JAMA. 2012;308(4):370\u20138.","journal-title":"JAMA"},{"issue":"11","key":"1427_CR78","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/cit103","volume":"56","author":"JA Mira","year":"2013","unstructured":"Mira JA, Rivero-Juarez A, Lopez-Cortes LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV\/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56(11):1646\u201353.","journal-title":"Clin Infect Dis"},{"key":"1427_CR79","doi-asserted-by":"crossref","unstructured":"Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451\u20139.","DOI":"10.1056\/NEJMoa032653"},{"issue":"5","key":"1427_CR80","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","volume":"351","author":"FJ Torriani","year":"2004","unstructured":"Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438\u201350.","journal-title":"N Engl J Med"},{"issue":"23","key":"1427_CR81","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","volume":"292","author":"F Carrat","year":"2004","unstructured":"Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839\u201348.","journal-title":"JAMA"},{"issue":"11","key":"1427_CR82","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/cid\/ciu675","volume":"59","author":"D Dieterich","year":"2014","unstructured":"Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon\/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis. 2014;59(11):1579\u201387.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1427_CR83","doi-asserted-by":"crossref","first-page":"e0125080","DOI":"10.1371\/journal.pone.0125080","volume":"10","author":"K Neukam","year":"2015","unstructured":"Neukam K, Munteanu DI, Rivero-Juarez A, et al. Boceprevir or telaprevir based triple therapy against chronic hepatitis C in HIV coinfection: real-life safety and efficacy. PLoS One. 2015;10(4):e0125080.","journal-title":"PLoS One"},{"issue":"4","key":"1427_CR84","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","volume":"312","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353\u201361.","journal-title":"JAMA"},{"issue":"9973","key":"1427_CR85","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","volume":"385","author":"JM Molina","year":"2015","unstructured":"Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385(9973):1098\u2013106.","journal-title":"Lancet"},{"key":"1427_CR86","doi-asserted-by":"crossref","unstructured":"Bhattacharya D, Belperio PS, Shahoumian TA, et al. Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis. 2017;64(12):1711\u201320.","DOI":"10.1093\/cid\/cix111"},{"issue":"12","key":"1427_CR87","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","volume":"313","author":"MS Sulkowski","year":"2015","unstructured":"Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223\u201331.","journal-title":"JAMA"},{"issue":"8","key":"1427_CR88","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","volume":"2","author":"JK Rockstroh","year":"2015","unstructured":"Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319\u201327.","journal-title":"Lancet HIV"},{"key":"1427_CR89","doi-asserted-by":"crossref","unstructured":"Wyles D, Brau N, Kottilil S, et al. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clin Infect Dis. 2017;65(1):6\u201312.","DOI":"10.1093\/cid\/cix260"},{"key":"1427_CR90","doi-asserted-by":"crossref","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714\u201325.","DOI":"10.1056\/NEJMoa1503153"},{"issue":"8","key":"1427_CR91","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/tri.12329","volume":"27","author":"N Akamatsu","year":"2014","unstructured":"Akamatsu N, Sugawara Y, Kokudo N, et al. Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int. 2014;27(8):767\u201374.","journal-title":"Transpl Int"},{"issue":"2","key":"1427_CR92","doi-asserted-by":"crossref","first-page":"124","DOI":"10.14218\/JCTH.2013.00002","volume":"2","author":"C Bunchorntavakul","year":"2014","unstructured":"Bunchorntavakul C, Reddy KR. Management of hepatitis C before and after liver transplantation in the era of rapidly evolving therapeutic advances. J Clin Transl Hepatol. 2014;2(2):124\u201333.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"1427_CR93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2013.08.018","volume":"60","author":"A Coilly","year":"2014","unstructured":"Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60(1):78\u201386.","journal-title":"J Hepatol"},{"key":"1427_CR94","doi-asserted-by":"crossref","unstructured":"Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transpl. 2009;9(8):1707\u201313.","DOI":"10.1111\/j.1600-6143.2009.02702.x"},{"issue":"2","key":"1427_CR95","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","volume":"49","author":"M Berenguer","year":"2008","unstructured":"Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49(2):274\u201387.","journal-title":"J Hepatol"},{"issue":"9","key":"1427_CR96","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/TP.0000000000000166","volume":"98","author":"T Ikegami","year":"2014","unstructured":"Ikegami T, Yoshizumi T, Kato M, et al. Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Transplantation. 2014;98(9):994\u20139.","journal-title":"Transplantation"},{"issue":"5","key":"1427_CR97","doi-asserted-by":"crossref","first-page":"1132\u20139e1","DOI":"10.1053\/j.gastro.2012.01.030","volume":"142","author":"J Levitsky","year":"2012","unstructured":"Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142(5):1132\u20139e1.","journal-title":"Gastroenterology"},{"issue":"3","key":"1427_CR98","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jhep.2017.03.006","volume":"67","author":"LS Belli","year":"2017","unstructured":"Belli LS, Duvoux C, Berenguer M, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017;67(3):585\u2013602.","journal-title":"J Hepatol"},{"issue":"1","key":"1427_CR99","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","volume":"148","author":"M Charlton","year":"2015","unstructured":"Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108\u201317.","journal-title":"Gastroenterology"},{"key":"1427_CR100","doi-asserted-by":"crossref","unstructured":"Ikegami T, Ueda Y, Akamatsu N, et al. Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: a Japanese multicenter experience. Clin Transplant. 2017;31(11):e13109.","DOI":"10.1111\/ctr.13109"},{"issue":"6","key":"1427_CR101","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","volume":"16","author":"M Manns","year":"2016","unstructured":"Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685\u201397.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1427_CR102","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s00535-017-1310-9","volume":"52","author":"Y Ueda","year":"2017","unstructured":"Ueda Y, Ikegami T, Akamatsu N, et al. Treatment with sofosbuvir and ledipasvir without ribavirin for 12\u00a0weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2017;52(8):986\u201391.","journal-title":"J Gastroenterol"},{"issue":"5","key":"1427_CR103","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","volume":"63","author":"F Poordad","year":"2016","unstructured":"Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493\u2013505.","journal-title":"Hepatology"},{"issue":"4","key":"1427_CR104","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/lt.24416","volume":"22","author":"RJ Fontana","year":"2016","unstructured":"Fontana RJ, Brown RS Jr, Moreno-Zamora A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016;22(4):446\u201358.","journal-title":"Liver Transpl"},{"issue":"6","key":"1427_CR105","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.27770","volume":"61","author":"S Pungpapong","year":"2015","unstructured":"Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61(6):1880\u20136.","journal-title":"Hepatology"},{"issue":"1","key":"1427_CR106","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/lt.24366","volume":"22","author":"RS Brown Jr","year":"2016","unstructured":"Brown RS Jr, O\u2019Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22(1):24\u201333.","journal-title":"Liver Transpl"},{"key":"1427_CR107","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Stepanova M, Sulkowski M, et al. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the ASTRAL-5 study. Liver Int. 2017;37:1796\u2013804.","DOI":"10.1111\/liv.13462"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-017-1427-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T06:23:35Z","timestamp":1751178215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-017-1427-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1007\/s00535-017-1427-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732398501.793545888","asserted-by":"object"}]},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]}}}